Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | RAB9A | P51151 | 8/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | CLK1 | P49759 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587931 | 0.85 | POLB (0.71) | POLBNPC1RAB9AMAPTCLK1 | |
| SCHEMBL15096727 | 0.85 | POLB (1.00) | POLBNPC1RAB9AMAPTCLK1 | |
| SCHEMBL3586328 | 0.84 | RAB9A (0.77) | POLBNPC1RAB9AMAPTKMT2A | |
| SCHEMBL3595563 | 0.84 | L3MBTL1 (0.77) | POLBNPC1RAB9AMAPTKMT2A | |
| SCHEMBL42334 | 0.83 | RAB9A (0.97) | POLBNPC1RAB9AMAPTKMT2A | |
| SCHEMBL1539906 | 0.79 | LCK (0.60) | POLBNPC1RAB9AMAPTKMT2A | |
| SCHEMBL15096728 | 0.78 | NPC1 (0.69) | POLBNPC1RAB9AMAPTCLK1 | |
| SCHEMBL19831002 | 0.78 | RAB9A (0.70) | POLBNPC1RAB9AMAPTCLK1 | |
| Trifluoroacetic Acid SCHEMBL6104602 | 0.76 | RAB9A (0.82) | POLBNPC1RAB9AMAPTKMT2A | |
| SCHEMBL1540033 | 0.76 | LCK (0.74) | NPC1RAB9AKMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541457-B2 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2013-09-24 | — | — | US | claimed |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2013-04-18 | — | — | US | claimed |
| EP-2540296-A1 | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | claimed |
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | claimed |
| US-8541457-B2 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2013-09-24 | — | — | US | disclosed |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| EP-2540296-A1 | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | disclosed |
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | disclosed |
| EP-2029138-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007130075-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | POLB 3214/4885NPC1 305/4885RAB9A 2428/4885 |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | POLB 3199/4885NPC1 298/4885RAB9A 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.